Literature DB >> 6187708

Characterization of anti-hepatitis B surface antigen monoclonal antibodies.

R C Kennedy, I Ionescu-Matiu, K Adler-Storthz, R D Henkel, Y Sanchez, G R Dreesman.   

Abstract

17 monoclonal antibodies generated against purified hepatitis B surface antigen (HBsAg), subtype ayw, were characterized by solid-phase radioimmunoassays. Eleven of these antibodies had specificity against the group-specific alpha determinant of HBsAg, two demonstrated antibody activity against the w HBsAg subtype, one against human serum albumin, and three against human IgG. All monoclonal antibodies were of the IgG class.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6187708     DOI： 10.1159/000149354

Source DB:  PubMed          Journal:  Intervirology        ISSN： 0300-5526            Impact factor:   1.763


  4 in total

1.  Immunocapture enzyme-linked immunosorbent assay for assessment of in vitro potency of recombinant hepatitis B vaccines.

Authors:  Rajalakshmi Shanmugham; Nagarajan Thirumeni; Varaprasada Sankarashetty Rao; Vidyasagar Pitta; Saranyarevathy Kasthuri; Nagendrakumar Balasubramanian Singanallur; Rajendra Lingala; Lakshmi Narsu Mangamoori; Srinivasan Alwar Villuppanoor
Journal:  Clin Vaccine Immunol       Date:  2010-06-30

2.  Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange.

Authors:  Georges Abou-Jaoudé; Camille Sureau
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

3.  Molecular analysis of hepatitis B virus "a" determinant in asymptomatic and symptomatic Mexican carriers.

Authors:  Martha-Eugenia Ruiz-Tachiquín; Hilda-Alicia Valdez-Salazar; Vicencio Juárez-Barreto; Margarita Dehesa-Violante; Javier Torres; Onofre Muñoz-Hernández; Ma-Teresa Alvarez-Muñoz
Journal:  Virol J       Date:  2007-01-11       Impact factor: 4.099

4.  Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies.

Authors:  R C Kennedy; G R Dreesman; J S Butel; R E Lanford
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.